- Truist Financial has increased its price target for Incyte (NASDAQ: INCY) to $105.00, indicating a potential 1.73% upside.
- Incyte secured regulatory approval for its drug Minjuvi® in Japan, expanding its market reach for blood cancer treatments.
- Positive Phase II results for zilurgisertib, a rare bone disease treatment, led to FDA Priority Review, accelerating its development timeline.
An analyst at Truist Financial has increased the price target for Incyte to $105.00. Incyte is a biopharmaceutical company that discovers, develops, and sells its own medicines. The new target suggests a potential 1.73% upside from the stock’s price of $103.21 at the time of the announcement, reflecting positive developments.
This optimism is supported by recent regulatory success. As highlighted by Business Wire, Incyte’s subsidiary in Japan received approval for Minjuvi®. The drug will be used to treat adults with a specific type of recurring blood cancer, opening up a new market for the company and its treatments.
Further positive news comes from Incyte’s drug pipeline. In partnership with Mirum Pharmaceuticals, the company reported positive Phase II results for zilurgisertib, a treatment for a rare bone disease, as reported by Zacks. The U.S. Food and Drug Administration (FDA) accepted its application and granted it Priority Review, which shortens the agency’s review timeline.
The market is reacting positively to these events. Shares of Incyte are currently trading at $103.66, a daily increase of 5.54%. The stock has seen significant activity, with a trading volume of approximately 2.17 million shares, showing strong investor interest in the company.
Over the past year, the stock has traded between a low of $66.74 and a high of $112.29. The company currently has a market capitalization of around $20.71 billion. Market capitalization is the total value of a company’s shares and is used to understand its size.
